Patents by Inventor Guy Goldberg
Guy Goldberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108643Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: ApplicationFiled: September 12, 2023Publication date: April 4, 2024Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Patent number: 11931463Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: GrantFiled: August 20, 2021Date of Patent: March 19, 2024Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Patent number: 11786541Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: GrantFiled: August 13, 2021Date of Patent: October 17, 2023Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Publication number: 20230106564Abstract: A multi-functional tag for marking cultivated plants and agricultural product throughout the whole plant and product cycle.Type: ApplicationFiled: October 2, 2022Publication date: April 6, 2023Inventors: Guy GOLDBERG, Michal Yanuv MAX
-
Publication number: 20220062188Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: ApplicationFiled: August 20, 2021Publication date: March 3, 2022Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Patent number: 11225371Abstract: A valve assembly (100, 500) for a pressurised or pressurisable container of an aerosol spray device is disclosed, wherein a valve stem (120) of the valve assembly (100, 500) is moveable between: a closed position in which a first sealing means (144) is biased against a second sealing means (148, 548) by a biasing means (146) such that a housing inlet (112) is not in fluid communication with an at least one valve stem inlet (178, 184); and an open position in which the first sealing means (144) is displaced from the second sealing means (148, 548) by a proximal end (174) of the valve stem (120) such that the housing inlet (112) is in fluid communication with the at least one valve stem inlet (178, 184), wherein, in the open position, a flow path is created from the housing inlet (112), around the outside of the first sealing means (144), and to the at least one valve stem inlet (178, 184).Type: GrantFiled: March 28, 2018Date of Patent: January 18, 2022Assignee: The Salford Valve Company LTDInventors: Ghasem Nasr, Thomas Guy Goldberg, Greig Tulloch, Amir Nourian
-
Publication number: 20210369754Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: ApplicationFiled: August 13, 2021Publication date: December 2, 2021Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Patent number: 11135172Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: GrantFiled: July 18, 2019Date of Patent: October 5, 2021Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Patent number: 11090325Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: GrantFiled: January 24, 2020Date of Patent: August 17, 2021Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Publication number: 20210107728Abstract: A valve assembly (100, 500) for a pressurised or pressurisable container of an aerosol spray device is disclosed, wherein a valve stem (120) of the valve assembly (100, 500) is moveable between: a closed position in which a first sealing means (144) is biased against a second sealing means (148, 548) by a biasing means (146) such that a housing inlet (112) is not in fluid communication with an at least one valve stem inlet (178, 184); and an open position in which the first sealing means (144) is displaced from the second sealing means (148, 548) by a proximal end (174) of the valve stem (120) such that the housing inlet (112) is in fluid communication with the at least one valve stem inlet (178, 184), wherein, in the open position, a flow path is created from the housing inlet (112), around the outside of the first sealing means (144), and to the at least one valve stem inlet (178, 184).Type: ApplicationFiled: March 28, 2018Publication date: April 15, 2021Inventors: Ghasem Nasr, Thomas Guy Goldberg, Greig Tulloch, Amir Nourian
-
Patent number: 10898439Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: GrantFiled: February 13, 2019Date of Patent: January 26, 2021Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Publication number: 20200253933Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.Type: ApplicationFiled: April 29, 2020Publication date: August 13, 2020Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
-
Patent number: 10668050Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.Type: GrantFiled: May 26, 2017Date of Patent: June 2, 2020Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
-
Publication number: 20200155585Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Publication number: 20200151531Abstract: A tuned radio frequency identification (RFID) label retrofittable to an article of manufacture, comprising: an RFID tag having a lower side and an upper side opposite the lower side, the lower side configured to rest against an article of manufacture; a cushioning layer having a lower side and an upper side opposite the lower side, the lower side covering the RFID tag, the cushioning layer attached to the upper side of the RFID tag by a first adhesive layer; and a skirt layer having a lower side attached by a second adhesive layer to the upper side of the cushioning layer.Type: ApplicationFiled: November 11, 2019Publication date: May 14, 2020Inventors: Guy GOLDBERG, Osnat GUR
-
Patent number: 10543222Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: GrantFiled: May 2, 2018Date of Patent: January 28, 2020Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Publication number: 20190336451Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: ApplicationFiled: July 18, 2019Publication date: November 7, 2019Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Patent number: 10357020Abstract: A livestock pasture display tag of a type used under harsh agricultural conditions, the tag comprising: (i) a thin, substantially, flat planar flexible display having a thickness, a front planar surface and a back planar surface, both surfaces are substantially parallel to a longitudinal axis positioned between surfaces; at least one of said surfaces is having a display section in which the livestock animal indicia is displayed; (ii) an anchoring section for fixedly securing the improved livestock pasture display tag to a body part surface of the livestock animal; and (iii) a permanent pressure sensitive encapsulation zone.Type: GrantFiled: April 8, 2016Date of Patent: July 23, 2019Assignee: TADBIK ADVANCED TECHNOLOGIES LTD (TAT)Inventors: Guy Goldberg, Gili Drori
-
Publication number: 20190175512Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: ApplicationFiled: February 13, 2019Publication date: June 13, 2019Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Patent number: 10238606Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: GrantFiled: March 22, 2017Date of Patent: March 26, 2019Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin